{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:51:17Z","timestamp":1761562277388,"version":"3.44.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.virusres.2017.08.006","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T17:46:50Z","timestamp":1504201610000},"page":"140-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Polymorphisms associated with resistance to protease inhibitors in na\u00efve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K"],"prefix":"10.1016","volume":"240","author":[{"given":"Alfredo P.","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s C.A.","family":"Culasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula S.","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanesa","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo H.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezequiel","family":"Ridruejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico A.","family":"Di Lello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2017.08.006_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2016.07.003","article-title":"Protease inhibitors drug resistance mutations in turkish patients with chronic hepatitis C","volume":"50","author":"Altunok","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.virusres.2017.08.006_bib0010","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/jvh.12051","article-title":"The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank","volume":"20","author":"Alves","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.virusres.2017.08.006_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3851\/IMP2821","article-title":"Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C","volume":"20","author":"Applegate","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virusres.2017.08.006_bib0020","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jmv.23545","article-title":"Hepatitis C virus subtyping based on sequencing of the C\/E1 and NS5B genomic regions in comparison to a commercially available line probe assay","volume":"85","author":"Av\u00f3","year":"2013","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virusres.2017.08.006_bib0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2017.08.006_bib0030","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors","volume":"54","author":"Bae","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virusres.2017.08.006_bib0035","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cmi.2015.07.017","article-title":"Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK","volume":"21","author":"Beloukas","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.virusres.2017.08.006_bib0040","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virusres.2017.08.006_bib0045","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nmeth.2109","article-title":"jModelTest 2: more models, new heuristics and parallel computing","volume":"9","author":"Darriba","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.virusres.2017.08.006_bib0050","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/jmv.24015","article-title":"Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches","volume":"86","author":"de Carvalho","year":"2014","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virusres.2017.08.006_bib0055","doi-asserted-by":"crossref","first-page":"ofv043","DOI":"10.1093\/ofid\/ofv043","article-title":"Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors","volume":"2","author":"De Luca","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.virusres.2017.08.006_bib0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.virusres.2016.07.008","article-title":"Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: their relevance for developing countries","volume":"223","author":"Echeverr\u00eda","year":"2016","journal-title":"Virus Res."},{"key":"10.1016\/j.virusres.2017.08.006_bib0065","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/nar\/gkh340","article-title":"MUSCLE: multiple sequence alignment with high accuracy and high throughput","volume":"32","author":"Edgar","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"4 (Suppl. 3)","key":"10.1016\/j.virusres.2017.08.006_bib0070","doi-asserted-by":"crossref","first-page":"19741","DOI":"10.7448\/IAS.17.4.19741","article-title":"Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV\/HCV co-infected patients in a Berlin laboratory","volume":"17","author":"Ehret","year":"2014","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.virusres.2017.08.006_bib0075","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2017.08.006_bib0080","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","article-title":"Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent","volume":"63","author":"Forns","year":"2015","journal-title":"J. Hepatol."},{"issue":"January","key":"10.1016\/j.virusres.2017.08.006_bib0085","article-title":"HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients","author":"Gozlan","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virusres.2017.08.006_bib0090","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1128\/JCM.02209-14","article-title":"Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment","volume":"52","author":"Guelfo","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.virusres.2017.08.006_bib0095","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/10635150390235520","article-title":"A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood","volume":"52","author":"Guindon","year":"2003","journal-title":"Syst. Biol."},{"key":"10.1016\/j.virusres.2017.08.006_bib0100","first-page":"95","article-title":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT","volume":"41","author":"Hall","year":"1999","journal-title":"Nucl. Acids Symp. Ser."},{"issue":"10","key":"10.1016\/j.virusres.2017.08.006_bib0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1743-422X-10-57","article-title":"Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study","volume":"14","author":"Hoffmann","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.virusres.2017.08.006_bib0110","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciu696","article-title":"Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection","volume":"59","author":"Howe","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virusres.2017.08.006_bib0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jmv.24608","article-title":"Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir\/asunaprevir","volume":"89","author":"Ikeda","year":"2017","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virusres.2017.08.006_bib0120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.virusres.2017.08.006_bib0125","doi-asserted-by":"crossref","first-page":"e0163197","DOI":"10.1371\/journal.pone.0163197","article-title":"NS3 resistance-associated variants (RAVs) in patients infected with HCV genotype 1a in Spain","volume":"11","author":"Jimenez-Sousa","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2017.08.006_bib0130","doi-asserted-by":"crossref","first-page":"e0155869","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV] \u2013 a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents","volume":"11","author":"Kalaghatgi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2017.08.006_bib0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3851\/IMP2976","article-title":"Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection","volume":"21","author":"Kinugasa","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virusres.2017.08.006_bib0140","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.3748\/wjg.v22.i40.8910","article-title":"Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database","volume":"22","author":"Kliemann","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.virusres.2017.08.006_bib0145","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virusres.2017.08.006_bib0150","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1128\/JCM.03633-14","article-title":"Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin","volume":"53","author":"Larrat","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.virusres.2017.08.006_bib0155","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.virusres.2017.08.006_bib0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cld.332","article-title":"Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment","volume":"3","author":"Lin","year":"2014","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.virusres.2017.08.006_bib0165","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3851\/IMP2873","article-title":"Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection","volume":"20","author":"Lisboa-Neto","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virusres.2017.08.006_bib0170","doi-asserted-by":"crossref","first-page":"e105569","DOI":"10.1371\/journal.pone.0105569","article-title":"Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing","volume":"9","author":"Margeridon-Thermet","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2017.08.006_bib0175","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/infdis\/jiu613","article-title":"Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism","volume":"211","author":"McCloskey","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2017.08.006_bib0180","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virusres.2017.08.006_bib0185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcv.2014.06.023","article-title":"Patients eligible for treatment with simeprevir in a French center","volume":"61","author":"Morel","year":"2014","journal-title":"J. Clin. Virol."},{"issue":"7","key":"10.1016\/j.virusres.2017.08.006_bib0190","doi-asserted-by":"crossref","first-page":"e0182193","DOI":"10.1371\/journal.pone.0182193","article-title":"2017. NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b","volume":"12","author":"Neukam","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2017.08.006_bib0195","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/QAD.0000000000001263","article-title":"The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands","volume":"31","author":"Newsum","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.virusres.2017.08.006_bib0200","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3851\/IMP2964","article-title":"Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype 1-infected individuals","volume":"20","author":"Nguyen","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virusres.2017.08.006_bib0205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1743-422X-9-245","article-title":"Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients","volume":"9","author":"Paolucci","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.virusres.2017.08.006_bib0210","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1590\/S0074-02762012000200016","article-title":"Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs","volume":"107","author":"Peres-da-Silva","year":"2012","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.virusres.2017.08.006_bib0215","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2893.2010.01342.x","article-title":"Evidence for separation of HCV subtype 1a into two distinct clades","volume":"18","author":"Pickett","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.virusres.2017.08.006_bib0220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virusres.2017.08.006_bib0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virusres.2017.08.006_bib0230","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2017.08.006_bib0235","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2017.08.006_bib0240","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2015.02.005","article-title":"Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort","volume":"65","author":"Shepherd","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.virusres.2017.08.006_bib0245","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virusres.2017.08.006_bib0250","doi-asserted-by":"crossref","first-page":"11124","DOI":"10.1128\/JVI.01217-10","article-title":"Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing","volume":"84","author":"Verbinnen","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2017.08.006_bib0255","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jac\/dkr581","article-title":"Naturally occurring hepatitis C virus (HCV) NS3\/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy","volume":"67","author":"Vicenti","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virusres.2017.08.006_bib0260","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170217304872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170217304872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:06:11Z","timestamp":1759154771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170217304872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":52,"alternative-id":["S0168170217304872"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2017.08.006","relation":{},"ISSN":["0168-1702"],"issn-type":[{"type":"print","value":"0168-1702"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymorphisms associated with resistance to protease inhibitors in na\u00efve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2017.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}